Johnson & Johnson Hunts Dengue Fever Drug and 2 Other Dow Movers to Watch

Johnson & Johnson (NYSE:JNJ): Current price $86.86

The iconic U.S. company is searching for drugs with which to treat dengue fever by partnering with academic researchers in Belgium and the Wellcome Trust medical charity. Presently, there exists no drug treatment or vaccine for the mosquito-borne viral disease, which is also known as “breakbone fever” due to the excruciating pain it can cause.

The collaboration between J&J’s Janssen division and researchers at the University of Leuven, who get support from Wellcome, will build on the discovery of a series of chemical compounds which are quite potent in preventing the replication of dengue virus.

jnj-20130829